nimodipine, an l-type calcium channel blocker, can induce analgesia. however, it is not clear that this analgesic effect is at the level of spinal or supraspinal pain pathway. in addition, it has been reported that the analgesic effect of nifedipine, another l-type calcium channel blocker is related to the hpa axis, but there is no report indicating the role of this axis in the analgesic effect...

Nimodipine, an L-type calcium channel blocker, can induce analgesia. However, it is not clear that this analgesic effect is at the level of spinal or supraspinal pain pathway. In addition, it has been reported that the analgesic effect of nifedipine, another L-type calcium channel blocker is related to the HPA axis, but there is no report indicating the role of this axis in the analgesic eff...

we have previously evaluated the effect of nimodipine, l-type calcium channel blocker, on memory loss during spontaneous morphine withdrawal. in the present study the effect of nimodipine on memory loss in naloxone-induced morphine withdrawal mice was investigated. mice were made dependent by increasing doses of morphine for three days. object recognition task that was used for evaluation of me...

the protective effect of a l-type calcium channel blocker, nimodipine, on cell injury induced by oxygen-glucose deprivation (ogd) in pc12 cells was investigated. pc12 cells were exposed to in-vitro oxygen-glucose deprivation (30 minutes and 60 minutes respectively) in the presence or absence of nimodipine (10mm/l) in three different time schedules (pre-24h, pre-3h and concurrently). cellular vi...

OBJECTIVE The objective of this study was to find out the clinical variables correlated with repeated intra-arterial (IA) nimodipine infusions in patients with medically refractory cerebral vasospasm (CV) following subarachnoid hemorrhage (SAH). MATERIALS AND METHODS During the 36 months between January 2011 and December 2013, 275 patients were treated at our institute for SAH due to a ruptur...

Nimodipine is a Ca2+-channel antagonist mainly used for the management of aneurysmal subarachnoid hemorrhage (aSAH) to prevent cerebral vasospasms. However, it is not clear if the better outcome of nimodipine-treated patients is mainly due to vasodilatation or whether other cellular neuroprotective or neuregenerative effects of nimodipine are involved. We analysed PC12 cells after different str...

− The aim of this study was to investigate the effects of kaempferol on the pharmacokinetics of nimodipine in rats. Nimodipine and kaempferol interact with cytochrome P450 (CYP) enzymes and P-glycoprotein (P-gp), and the increase in the use of health supplements may result in kaempferol being taken concomitantly with nimodipine as a combination therapy to treat orprevent cardiovascular disease....

The reduced bioavailability of nimodipine after oral administration might not only be due to the metabolizing enzyme cytochrome P450 3A4(CYP3A4) but also to the P-glycoprotein efflux transporter in the small intestine. The aim of this study was to investigate the effects of baicalein on the pharmacokinetics of nimodipine in rats. The effect of baicalein on P-glycoprotein and CYP3A4 activity was...

As L-type voltage-gated calcium channels (VGCCs) control Ca(2+) influx and depolarisation of cardiac and vascular smooth muscle, they represent a specific therapeutic target for calcium channel blockers (CCBs), which are approved and widely used to treat hypertension, myocardial ischaemia and arrhythmias. L-type currents also play a role in calcium entry in the sensory cells of the inner ear. I...

A rapid, simple and reproducible HPLC method was developed and validated for the analysis of nimodipine (NM) and/or its metabolite, oxidized nimodipine (OX–NM) in rat cerebrospinal fluid (CSF) and artificial CSF. The NM and OX–NM were eluted in less than 10 min with no interferences from the endogenous CSF peaks. Analysis was carried out on a Eurospher Performance (RP-C18, 250 × 4.6 mm) column ...